This event is now over
ChanTest is hosting an event in Boston highlighting the latest advances and strategies for Ion Channel and GPCR screening & profiling for drug discovery and preclinical cardiac safety testing. Symposium presentations by both industrial and ChanTest scientists will highlight current and future strategies for effective drug development. A Q&A panel discussion will follow each session.
Morning Session: Ion Channel and GPCR Screening & Profiling
Afternoon Session: Preclinical Cardiac Safety Testing: the latest strategies for effectively predicting cardiac risk
There is no charge for this event. Continental breakfast and lunch are provided. The symposium will be followed by a brief reception - courtesy of ChanTest.
Trouble with your registration? Email us directly at firstname.lastname@example.org with your name and institution. One of our representatives will be in touch to confirm your participation.
ChanTest’s mission is to serve the research, drug discovery and drug development needs of customers worldwide with high-value solutions for ion channel and GPCR biology. Since its inception in 1998, the company has tested compounds for more than 500 global pharmaceutical and biotechnology companies and partners with them to speed the drug development process for the release of better, safer drugs. ChanTest offers integrated ion channel and GPCR services (GLP and non-GLP) and reagents; the company’s library of validated ion channel cell lines and pre-clinical cardiac risk assessment service portfolio are the most comprehensive commercially available today. Because of ChanTest’s seminal role in the pre-clinical cardiac safety field, along with the company’s uncompromising commitment to quality, ChanTest has been named the “most trusted and most used fee-for-service provider” for ion channel screening in an independent survey for the past five years. ChanTest is based in Cleveland, Ohio.